Gaurav Shah, MD, Chief Executive Officer & President of Rocket Pharmaceuticals explains the advantages that smaller biotech companies have in developing treatments for rare diseases.

Rocket Pharmaceuticals is currently developing gene therapies for a number of rare conditions, including Fanconi  anemia, Danon disease, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and infantile malignant osteopetrosis.

For more information, visit www.rocketpharma.com.

 

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.